RxDoctor Payments Data

Philip Oranburg, MD

Cardiovascular Disease · Boca Raton, FLNPI 1770534471

Payments from drug & device makers

$6,846in general payments, 2019–2025

Across 30 payments — averaging $228.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Endotronix, Inc.$5K
  • E.r. Squibb & Sons, L.L.C.$291
  • Amarin Pharma, Inc.$280
  • Boehringer Ingelheim$249
  • Abbott$174
  • Novo Nordisk$173
  • plus $678 from 8 others

What the payments were for

  • Food & beverage$1,82499%
  • Education$221%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,846 in reported general payments places this provider in the 65th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$521,508
Medicare patients
856
Services billed
9,189

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban275$292,317
XareltoRivaroxaban73$91,459
EntrestoSacubitril/Valsartan50$69,521
MounjaroTirzepatide27$30,051
Repatha SureclickEvolocumab40$29,815
MultaqDronedarone Hcl20$26,261
CrestorRosuvastatin Calcium16$12,552
OzempicSemaglutide13$11,839
Praluent PenAlirocumab19$9,396
TradjentaLinagliptin13$7,493
Rosuvastatin Calcium350$5,132
Metoprolol Succinate200$3,924
Atorvastatin Calcium319$3,718
Amlodipine Besylate245$2,380
Losartan Potassium162$1,809

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$124$292,317275 claims
Johnson & JohnsonXarelto$121$91,45973 claims
NovartisEntresto$62$69,52150 claims
AstraZenecaCrestor$57$12,55216 claims
Novo NordiskOzempic$173$11,83913 claims
Boehringer IngelheimTradjenta$249$7,49313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Boca Raton

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →